Goldenwell Biotech Inc
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
Goldenwell Biotech Inc (GWLL) - Total Liabilities
Latest total liabilities as of June 2025: $338.13K USD
Based on the latest financial reports, Goldenwell Biotech Inc (GWLL) has total liabilities worth $338.13K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Goldenwell Biotech Inc - Total Liabilities Trend (2020–2024)
This chart illustrates how Goldenwell Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Goldenwell Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Goldenwell Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Step One Clothing Limited
F:J6H
|
Germany | €10.13 Million |
|
Netlinkz Ltd
AU:NET
|
Australia | AU$28.13 Million |
|
Mobio Technologies Inc
V:MBO
|
Canada | CA$5.00 Million |
|
Crest Builder Holdings Bhd
KLSE:8591
|
Malaysia | RM1.03 Billion |
|
QNB Finans Finansal Kiralama AS
IS:QNBFL
|
Turkey | TL26.56 Billion |
|
Itera ASA
OL:ITERA
|
Norway | Nkr201.60 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Goldenwell Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Goldenwell Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Goldenwell Biotech Inc (2020–2024)
The table below shows the annual total liabilities of Goldenwell Biotech Inc from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $271.43K | +89.37% |
| 2023-12-31 | $143.33K | +206.39% |
| 2022-12-31 | $46.78K | -70.63% |
| 2021-12-31 | $159.26K | -- |
| 2020-12-31 | $0.00 | -- |